Opendata, web and dolomites


Clinical validation of a new diagnostic and monitoring PoC medical device based on quantification of biomarkers in tear fluids to improve the quality of eye health care

Total Cost €


EC-Contrib. €






Project "eyePoC" data sheet

The following table provides information about the project.


Organization address
postcode: 6700
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2014
 Duration (year-month-day) from 2014-10-01   to  2015-03-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HORUS PHARMA SAS FR (SAINT-LAURENT-DU-VAR) coordinator 50˙000.00
2    BIOFTALMIK S.L. ES (DERIO) participant 0.00


 Project objective

Ocular diseases are not only relevant social, sanitary and economic issues, but also a growing market opportunity in an increasingly ageing population. Ophthalmology is a health care area where the availability of easy to use point of care (PoC) medical devices based on biomarkers is fundamental for improving patient vision care, reducing number and frequency of sick leave and disability due to visual problems and for getting a significant reduction of overcrowding of ophthalmology units at health systems. The use of medical devices able to detect and measure biomarkers in human samples in a fast and non-invasive method will allow the easy introduction of these systems at the doctor’s office, thus enabling diagnosis of diseases in an objective manner and accurately monitoring of treatments effectiveness to be introduced into the standard clinical protocols. The present project is aimed to the clinical validation and market introduction of a device previously developed for ocular surface diseases (OSDs), named Tear Monitor and focused on diagnosis and monitoring of the Dry Eye and inflammation by measuring biomarkers in tears. For this purpose, two European SMEs specialised on ophthalmology establish a collaborative partnership to joint their respective expertises in a complementary synergism to reach the objectives proposed. Horus Pharma, a French pharmaceutical company, specialised on production, distribution and sales of pharmaceutical and biotech products for eye therapy and diagnostic; and Bioftalmik, a Spanish company specialised on biomarker discovery and development of medical devices for ophthalmology applications. This project is crucial for the economic growth and international expansion of both companies and constitutes the base for strategic development in the immediate future.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EYEPOC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EYEPOC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More